The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to its treatment options for pain relief. The hospital, which opened in ...

SMARTER SCREENINGS: The U.S. Food and Drug Administration (FDA) has approved the first artificial intelligence (AI) tool to predict breast cancer risk. 'WE WILL FIGHT': OpenAI CEO Sam Altman said ...

Phathom Pharmaceuticals shares are up over 100% after the FDA granted 10-year market exclusivity for Voquezna through 2032. The FDA updated its Orange Book to reflect full NCE+GAIN exclusivity ...

According to the FDA’s prescribing information on mifepristone, fewer than 0.5 percent of people taking the drug with misoprostol to end pregnancy experienced serious adverse reactions.

FDA reassures rare disease advocates that ‘being flexible’ is plan for gene therapy. At roundtable, Kennedy, Prasad, and others express openness to quick approvals.

Seventeen other Democratic-led or -leaning states, plus Washington D.C., are suing the FDA in Spokane, Washington, to loosen restrictions on the drug, Reuters reported in February.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...